VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This partially randomized phase I trial studies the side effects and how well sequential
dosing of vascular endothelial growth factor receptor (VEGFR)/platelet derived growth factor
receptor (PDGFR) dual kinase inhibitor X-82 and docetaxel works in treating patients with
solid tumors. VEGFR/PDGFR dual kinase inhibitor X-82 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
docetaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving VEGFR/PDGFR
dual kinase inhibitor X-82 and docetaxel one at a time instead of concurrently may work in
treating patients with solid tumors.